Correlation analysis of Insulin-like Growth Factor-1 level on severity in ischemic stroke patients: A cross-sectional study
Keywords:
ischemic stroke, severity, NIHSS, IGF-1Abstract
Background and aim: Our knowledge of the pathophysiology of stroke and its treatment strategies has greatly benefited from the application of biomarkers in the area. Insulin-like growth factor-1 (IGF-1), a neuroprotectant, is one likely biomarker for predicting the outcome of stroke. With its neuroprotective properties, IGF-1 is a potential biomarker for stroke prognostic prediction. The aim of this study to ascertain the relationship of serum IGF-1 levels with the severity of ischemic stroke patients.
Methods: This cross-sectional study involved 62 acute ischemic stroke patients and 21 normal controls. The study was conducted during October-November 2024 at several hospitals in Makassar, Indonesia. The assessment of serum IGF-1 concentrations and the assessment of stroke severity utilizing the National Institutes of Health Stroke Scale (NIHSS) were performed at the time of admission.
Results: Most of the ischemic stroke patients were male (54.8%) with a mean age of 57.91 ± 9.41 years. Most of the acute ischemic stroke samples had moderate severity stroke (51.6%). IGF-1 levels in acute ischemic stroke patients were significantly lower than the normal population of the same age, with mean IGF-1 levels of 0.420 ± 0.157 and 1.265 ± 2.653, respectively (p=0.007). There was no significant relationship between serum IGF-1 levels and stroke severity or fasting blood glucose levels at the beginning of admission.
Conclusions: IGF-1 levels are lower in ischemic stroke patients compared to the normal population, and there is no correlation between serum IGF-1 levels and stroke severity at the time of admission.
References
Shaheen H, Sobhy S, El Mously S, Niazi M, Gomaa M. Insulin-Like Growth Factor-1 in Acute Ischemic Stroke. Egypt J Neurol Psychiatry Neurosurg. 2018;54(1):42. doi:10.1186/s41983-018-0042-y
Armbrust M, Worthmann H, Dengler R, et al. Circulating Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic Stroke: Exp Clin Endocrinol Diabetes. 2017;125(07):485-491. doi:10.1055/s-0043-103965
Hayes CA, Valcarcel-Ares MN, Ashpole NM. Preclinical and clinical evidence of IGF-1 as a prognostic marker and acute intervention with ischemic stroke. J Cereb Blood Flow Metab. 2021;41(10):2475-2491. doi:10.1177/0271678X211000894
Arfan AR, Kurniawan LB, Arif M, Umar H, Nurahmi, Bahar B. Analysis of the Relationship between HbA1c and Serum IGF-1 Levels in Patients with T2DM. Indones J Clin Pathol Med Lab. 2023;29(3):277-281. doi:10.24293/ijcpml.v29i3.2151
Aleidi SM, Shayeb E, Bzour J, et al. Serum level of insulin-like growth factor-I in type 2 diabetic patients: impact of obesity. Horm Mol Biol Clin Investig. 2019;39(1):20190015. doi:10.1515/hmbci-2019-0015
Runtuwene IM, Akbar M, Bintang AK, Tammasse J, Muis A, Zainuddin AA. Effectivity of Repetitive Transcranial Magnetic Stimulation Improving Depressive Symptoms and Motoric Strength Ischemic Stroke. Nusant Med Sci J. 8(1):25-37.
Maulida, Akbar M, Bahar A, Masadah R, Tammasse J, Kaelan C. Analysis of blood pressure variability in lacunar and non-lacunar types acute ischemic strokes patients as a predictor of clinical outcomes. Acta Biomed Atenei Parm. 95(6):1-13. doi:10.23750/abm.v95i6.16635
Sucharew H, Khoury J, Moomaw CJ, et al. Profiles of the National Institutes of Health Stroke Scale Items as a Predictor of Patient Outcome. Stroke. 2013;44(8):2182-2187. doi:10.1161/STROKEAHA.113.001255
Chalos V, Van Der Ende NAM, Lingsma HF, et al. National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke. Stroke. 2020;51(1):282-290. doi:10.1161/STROKEAHA.119.026791
Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. Annu Rev Public Health. 2021;42(1):59-77. doi:10.1146/annurev-publhealth-090419-102644
Bergman M, Manco M, Satman I, et al. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes. Diabetes Res Clin Pract. 2024;209:111589. doi:10.1016/j.diabres.2024.111589
Yao Y, Zhu H, Zhu L, et al. A comprehensive contribution of genetic variations of the insulin-like growth factor 1 signalling pathway to stroke susceptibility. Atherosclerosis. 2020;296:59-65. doi:10.1016/j.atherosclerosis.2020.01.009
Mehrpour M, Rahatlou H, Hamzehpur N, Kia S, Safdarian M. Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke. Iran J Neurol. 2016;15(4):214-218.
Åberg ND, Åberg D, Jood K, et al. Altered levels of circulating insulin-like growth factor I (IGF-I) following ischemic stroke are associated with outcome - a prospective observational study. BMC Neurol. 2018;18(1):106. doi:10.1186/s12883-018-1107-3
Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Glob Health. 2017;2(2):e000298. doi:10.1136/bmjgh-2017-000298
Fan F. Menopause and Ischemic Stroke: A Brief Review. MOJ Toxicol. 2017;3(4). doi:10.15406/mojt.2017.03.00059
Åberg D, Jood K, Blomstrand C, et al. Serum IGF-I Levels Correlate to Improvement of Functional Outcome after Ischemic Stroke. J Clin Endocrinol Metab. 2011;96(7):E1055-E1064. doi:10.1210/jc.2010-2802
Genis L, Dávila D, Fernandez S, Pozo-Rodrigálvarez A, Martínez-Murillo R, Torres-Aleman I. Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury. F1000Research. 2014;3:28. doi:10.12688/f1000research.3-28.v2
Sohrabji F. Estrogen-IGF-1 interactions in neuroprotection: Ischemic stroke as a case study. Front Neuroendocrinol. 2015;36:1-14. doi:10.1016/j.yfrne.2014.05.003
Saber H, Himali JJ, Beiser AS, et al. Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study. Stroke. 2017;48(7):1760-1765. doi:10.1161/STROKEAHA.116.016563
De Smedt A, Brouns R, Uyttenboogaart M, et al. Insulin-Like Growth Factor I Serum Levels Influence Ischemic Stroke Outcome. Stroke. 2011;42(8):2180-2185. doi:10.1161/STROKEAHA.110.600783
Guan J, Bennet L, Gluckman PD, Gunn AJ. Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol. 2003;70(6):443-462. doi:10.1016/j.pneurobio.2003.08.002
Russo VC, Gluckman PD, Feldman EL, Werther GA. The Insulin-Like Growth Factor System and Its Pleiotropic Functions in Brain. Endocr Rev. 2005;26(7):916-943. doi:10.1210/er.2004-0024
Gunnell D, Miller LL, Rogers I, Holly JMP, and the ALSPAC Study Team. Association of Insulin-like Growth Factor I and Insulin-like Growth Factor–Binding Protein-3 With Intelligence Quotient Among 8- to 9-Year-Old Children in the Avon Longitudinal Study of Parents and Children. Pediatrics. 2005;116(5):e681-e686. doi:10.1542/peds.2004-2390
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.